keyword
https://read.qxmd.com/read/38655187/the-biased-apelin-receptor-agonist-mm07-reverses-sugen-hypoxia-induced-pulmonary-arterial-hypertension-as-effectively-as-the-endothelin-antagonist-macitentan
#1
JOURNAL ARTICLE
Thomas L Williams, Duuamene Nyimanu, Rhoda E Kuc, Richard Foster, Robert C Glen, Janet J Maguire, Anthony P Davenport
Introduction: Pulmonary arterial hypertension (PAH) is characterised by endothelial dysfunction and pathological vascular remodelling, resulting in the occlusion of pulmonary arteries and arterioles, right ventricular hypertrophy, and eventually fatal heart failure. Targeting the apelin receptor with the novel, G protein-biased peptide agonist, MM07, is hypothesised to reverse the developed symptoms of elevated right ventricular systolic pressure and right ventricular hypertrophy. Here, the effects of MM07 were compared with the clinical standard-of-care endothelin receptor antagonist macitentan...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38651330/exploring-therapeutic-targets-for-molecular-therapy-of-idiopathic-pulmonary-fibrosis
#2
REVIEW
Yue Li, Congshan Jiang, Wenhua Zhu, Shemin Lu, Hongchuan Yu, Liesu Meng
Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease with a poor prognosis. Idiopathic pulmonary fibrosis is characterized by repeated alveolar epithelial damage leading to abnormal repair. The intercellular microenvironment is disturbed, leading to continuous activation of fibroblasts and myofibroblasts, deposition of extracellular matrix, and ultimately fibrosis. Moreover, pulmonary fibrosis was also found as a COVID-19 complication. Currently, two drugs, pirfenidone and nintedanib, are approved for clinical therapy worldwide...
2024: Science Progress
https://read.qxmd.com/read/38651245/comparative-pharmacokinetics-and-safety-assessment-of-1st-and-2nd-generation-zinpentraxin-alfa-drug-products-in-healthy-volunteers-a-randomized-crossover-study
#3
JOURNAL ARTICLE
Tu H Mai, Rajbharan Yadav, Audrey Arjomandi, Christine Jung, Monika M Meier, Francis Donaldson, Rui Zhao, Han-Ting Ding, Joy C Hsu, Nikhil Kamath, Lin Pan
Zinpentraxin alfa is a recombinant form of the human pentraxin-2 that was studied in idiopathic pulmonary fibrosis (IPF). To improve the purity and yield of the drug material, a 2nd-generation drug product was developed. To characterize and compare the pharmacokinetic (PK) properties of the 1st- and 2nd-generation zinpentraxin alfa, PK studies were conducted in healthy volunteers (HVs). In a phase 1 randomized, double-blind, 2-sequence crossover, sequential 2-stage study (ISRCTN59409907), single intravenous (IV) doses of 1st- and 2nd-generation zinpentraxin alfa at 10 mg/kg were studied with a blinded interim analysis (IA) at the end of stage 1...
April 23, 2024: Clinical Pharmacology in Drug Development
https://read.qxmd.com/read/38649414/cerastecins-inhibit-membrane-lipooligosaccharide-transport-in-drug-resistant-acinetobacter-baumannii
#4
JOURNAL ARTICLE
Hao Wang, Andrii Ishchenko, Jason Skudlarek, Pamela Shen, Liudmila Dzhekieva, Ronald E Painter, Yun-Ting Chen, Marina Bukhtiyarova, Andrew Leithead, Rodger Tracy, Kerim Babaoglu, Carolyn Bahnck-Teets, Alexei Buevich, Tamara D Cabalu, Marc Labroli, Henry Lange, Ying Lei, Wei Li, Jian Liu, Paul A Mann, Tao Meng, Helen J Mitchell, James Mulhearn, Giovanna Scapin, Deyou Sha, Anthony W Shaw, Qian Si, Ling Tong, Chengwei Wu, Zhe Wu, Jing Chen Xiao, Min Xu, Li-Kang Zhang, David McKenney, Randy R Miller, Todd A Black, Andrew Cooke, Carl J Balibar, Daniel J Klein, Izzat Raheem, Scott S Walker
Carbapenem-resistant Acinetobacter baumannii infections have limited treatment options. Synthesis, transport and placement of lipopolysaccharide or lipooligosaccharide (LOS) in the outer membrane of Gram-negative bacteria are important for bacterial virulence and survival. Here we describe the cerastecins, inhibitors of the A. baumannii transporter MsbA, an LOS flippase. These molecules are potent and bactericidal against A. baumannii, including clinical carbapenem-resistant Acinetobacter baumannii isolates...
April 22, 2024: Nature Microbiology
https://read.qxmd.com/read/38643941/development-of-a-dry-powder-insufflation-device-with-application-in-in-vitro-cell-based-assays-in-the-context-of-respiratory-delivery
#5
JOURNAL ARTICLE
Jorge F Pontes, Hermínio P Diogo, Eusébio Conceição, Maria P Almeida, Rui M Borges Dos Santos, Ana Grenha
Research on pharmaceutical dry powders has been increasing worldwide, along with increased therapeutic strategies for an application through the pulmonary or the nasal routes. In vitro methodologies and tests that mimic the respiratory environment and the process of inhalation itself are, thus, essential. The literature frequently reports cell-based in vitro assays that involve testing the dry powders in suspension. This experimental setting is not adequate, as both the lung and the nasal cavity are devoid of abundant liquid...
April 19, 2024: European Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38640446/liposomes-for-inhalation
#6
JOURNAL ARTICLE
Hui Xin Ong, Daniela Traini, Paul M Young
Inhalation of liposomes formulated with phospholipids similar to endogenous lung surfactants and lipids offers biocompatibility and versatility within the pulmonary medicine field to treat a range of diseases such as lung cancer, cystic fibrosis and lung infections. Manipulation of the physicochemical properties of liposomes enables innovative design of the carrier to meet specific delivery, release and targeting requirements. This delivery system offers several benefits: improved pharmacokinetics with reduced toxicity, enhanced therapeutic efficacy, increased delivery of poorly soluble drugs, taste masking, biopharmaceutics degradation protection and targeted cellular therapy...
April 2024: Journal of Aerosol Medicine and Pulmonary Drug Delivery
https://read.qxmd.com/read/38633612/the-traditional-uses-pharmacology-and-phytochemistry-of-peucedanum-praeruptorum-dunn
#7
REVIEW
Qiongxiao Wang, Qingmei Sun, Qinger Huang, Luping Qin, Bo Zhu
Bai Hua Qian Hu (Qianhu; Peucedanum praeruptorum Dunn) is a classical medicinal plant traditionally prescribed for respiratory ailments, including cough, pulmonary hypertension, and asthma. In this review, we summarize the research progress of the toxicology, pharmacokinetics, pharmacology, phytochemistry, botany, quality control, and traditional uses of P. praeruptorum in order to support future investigations into the scientific and therapeutic promise of this important medicinal plant. Information pertaining to P...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38628892/characterization-and-evaluation-of-nano-niosomes-encapsulating-docetaxel-against-human-breast-pancreatic-and-pulmonary-adenocarcinoma-cancer-cell-lines
#8
JOURNAL ARTICLE
Mohammadreza Ajdari, Aliyeh Ranjbar, Khashayar Karimian, Maryam Karimi, Hossein Heli, Naghmeh Sattarahmady
BACKGROUND: Docetaxel (DXL) is an antineoplastic agent for cancer treatment, the therapeutic efficiency of which is limited due to low solubility, hydrophobicity, and tissue specificity. OBJECTIVE: In this study, nano-niosomes were introduced for improving therapeutic index of DXL. MATERIAL AND METHODS: In this experimental study, two nano-niosomes were synthesized using Span 20® and Span 80® and a thin film hydration method with DXL loading (DXL-Span20 and DXL-Span80)...
April 2024: Journal of Biomedical Physics & Engineering
https://read.qxmd.com/read/38628643/pharmacokinetics-of-desflurane-uptake-and-disposition-in-piglets
#9
JOURNAL ARTICLE
Chih-Cherng Lu, Shung-Tai Ho, Oliver Yao-Pu Hu, Cheng-Huei Hsiong, Yuan-Chen Cheng, Che-Hao Hsu, Tso-Chou Lin
INTRODUCTION: Many respiratory but few arterial blood pharmacokinetics of desflurane uptake and disposition have been investigated. We explored the pharmacokinetic parameters in piglets by comparing inspiratory, end-tidal, arterial blood, and mixed venous blood concentrations of desflurane. METHODS: Seven piglets were administered inspiratory 6% desflurane by inhalation over 2 h, followed by a 2-h disposition phase. Inspiratory and end-tidal concentrations were detected using an infrared analyzer...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38626911/the-clinical-translation-of-%C3%AE-humulene-a-scoping-review
#10
JOURNAL ARTICLE
Nishaanth Dalavaye, Martha Nicholas, Manaswini Pillai, Simon Erridge, Mikel H Sodergen
α-humulene, a sesquiterpene found in essential oils of various plant species, has garnered interest due to its potential therapeutic applications. This scoping review aims to consolidate α-humulene's evidence base, informing clinical translation and guiding future research directions. A scoping review was conducted of EMBASE, MEDLINE and PubMed databases up to 14th July 2023. All studies describing original research on α-humulene extraction, pre-clinical and clinical research were included for review...
April 16, 2024: Planta Medica
https://read.qxmd.com/read/38610717/cutting-edge-techniques-and-drugs-for-the-treatment-of-pulmonary-embolism-current-knowledge-and-future-perspectives
#11
REVIEW
Lorenzo Falsetti, Emanuele Guerrieri, Vincenzo Zaccone, Giovanna Viticchi, Silvia Santini, Laura Giovenali, Graziana Lagonigro, Stella Carletti, Linda Elena Gialluca Palma, Nicola Tarquinio, Gianluca Moroncini
Pulmonary embolism (PE) is a potentially life-threatening condition requiring prompt diagnosis and treatment. Recent advances have led to the development of newer techniques and drugs aimed at improving PE management, reducing its associated morbidity and mortality and the complications related to anticoagulation. This review provides an overview of the current knowledge and future perspectives on PE treatment. Anticoagulation represents the first-line treatment of hemodynamically stable PE, direct oral anticoagulants being a safe and effective alternative to traditional anticoagulation: these drugs have a rapid onset of action, predictable pharmacokinetics, and low bleeding risk...
March 28, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38596536/a-toxicology-study-of-csf2ra-complementation-and-pulmonary-macrophage-transplantation-therapy-of-hereditary-pap-in-mice
#12
JOURNAL ARTICLE
Paritha Arumugam, Brenna C Carey, Kathryn A Wikenheiser-Brokamp, Jeffrey Krischer, Matthew Wessendarp, Kenjiro Shima, Claudia Chalk, Jennifer Stock, Yan Ma, Diane Black, Michelle Imbrogno, Margaret Collins, Dan Justin Kalenda Yombo, Haripriya Sakthivel, Takuji Suzuki, Carolyn Lutzko, Jose A Cancelas, Michelle Adams, Elizabeth Hoskins, Dawn Lowe-Daniels, Lilith Reeves, Anne Kaiser, Bruce C Trapnell
Pulmonary macrophage transplantation (PMT) is a gene and cell transplantation approach in development as therapy for hereditary pulmonary alveolar proteinosis (hPAP), a surfactant accumulation disorder caused by mutations in CSF2RA/B (and murine homologs). We conducted a toxicology study of PMT of Csf2ra gene-corrected macrophages (mGM-Rα+ Mϕs) or saline-control intervention in Csf2ra KO or wild-type (WT) mice including single ascending dose and repeat ascending dose studies evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics...
June 13, 2024: Molecular Therapy. Methods & Clinical Development
https://read.qxmd.com/read/38582282/a-novel-chitosan-coated-leciplex-loaded-with-ambrisentan-as-a-possible-pulmonary-nanosystem-optimization-characterization-and-pharmacokinetics-assessments
#13
JOURNAL ARTICLE
Hussein M Eid, Toqa H El-Sayed, Adel A Ali, Heba M Aboud
The purpose of this research was to formulate, optimize, and characterize ambrisentan chitosan-coated LeciPlex (AMS-CTS-LPX) to increase the therapeutic effectiveness and bioavailability of ambrisentan. A central composite design (CCD) was implemented to assess the impact of various factors on the production of AMS-CTS-LPX and to identify the optimum formulation via the use of Design Expert® software. The assembly of AMS-CTS-LPX was conducted using a single-step process. Subsequently, the optimal formulation was chosen and subjected to further assessments...
April 4, 2024: Journal of Pharmaceutical Sciences
https://read.qxmd.com/read/38575778/transmucosal-delivery-of-peptides-and-proteins-through-nanofibers-current-status-and-emerging-developments
#14
REVIEW
Priyanka Gavali, Jagruti Desai, Pranav Shah, Sujata Sawarkar
Advancements in recombinant DNA technology have made proteins and peptides available for diagnostic and therapeutic applications, but their effectiveness when taken orally leads to poor patient compliance, requiring clinical administration. Among the alternative routes, transmucosal delivery has the advantage of being noninvasive and bypassing hepato-gastrointestinal clearance. Various mucosal routes-buccal, nasal, pulmonary, rectal, and vaginal-have been explored for delivering these macromolecules. Nanofibers, due to their unique properties like high surface-area-to-volume ratio, mechanical strength, and improved encapsulation efficiency, serve as promising carriers for proteins and peptides...
April 4, 2024: AAPS PharmSciTech
https://read.qxmd.com/read/38568399/therapeutic-effects-of-tetrandrine-in-inflammatory-diseases-a-comprehensive-review
#15
REVIEW
Jiawen Song, Yushi Liu, Yurou Guo, Minghao Yuan, Wenxiao Zhong, Jiamei Tang, Yiping Guo, Li Guo
Inflammation can be triggered by any factor. The primary pathological manifestations can be summarized as the deterioration, exudation, and proliferation of local tissues, which can cause systemic damage in severe cases. Inflammatory lesions are primarily localized but may interact with body systems to cause provocative storms, parenchymal organ lesions, vascular and central nervous system necrosis, and other pathologic responses. Tetrandrine (TET) is a bisbenzylquinoline alkaloid extracted from the traditional Chinese herbal medicine Stephania tetrandra, which has been shown to have significant efficacy in inflammatory conditions such as rheumatoid arthritis, hepatitis, nephritis, etc...
April 3, 2024: Inflammopharmacology
https://read.qxmd.com/read/38563382/enantiomer-specific-cardiovascular-effects-of-the-ketone-body-3-hydroxybutyrate
#16
JOURNAL ARTICLE
Nigopan Gopalasingam, Niels Moeslund, Kristian Hylleberg Christensen, Kristoffer Berg-Hansen, Jacob Seefeldt, Casper Homilius, Erik Nguyen Nielsen, Mie Ringgaard Dollerup, Aage K Alstrup Olsen, Mogens Johannsen, Ebbe Boedtkjer, Niels Møller, Hans Eiskjær, Lars Christian Gormsen, Roni Nielsen, Henrik Wiggers
BACKGROUND: The ketone body 3-hydroxybutyrate (3-OHB) increases cardiac output (CO) by 35% to 40% in healthy people and people with heart failure. The mechanisms underlying the effects of 3-OHB on myocardial contractility and loading conditions as well as the cardiovascular effects of its enantiomeric forms, D-3-OHB and L-3-OHB, remain undetermined. METHODS AND RESULTS: Three groups of 8 pigs each underwent a randomized, crossover study. The groups received 3-hour infusions of either D/L-3-OHB (racemic mixture), 100% L-3-OHB, 100% D-3-OHB, versus an isovolumic control...
April 2, 2024: Journal of the American Heart Association
https://read.qxmd.com/read/38562706/dynamic-pet-reveals-compartmentalized-brain-and-lung-tissue-antibiotic-exposures
#17
Sanjay Jain, Xueyi Chen, Bhavatharini Arun, Oscar Nino Meza, Mona Sarhan, Medha Singh, Byeonghoon Jeon, Kishor Mane, Maunank Shah, Elizabeth Tucker, Laurence Carroll, Joel Freundlich, Charles Peloquin, Vijay Ivaturi
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we performed first-in-human dynamic 18 F-pretomanid positron emission tomography (PET) studies in eight human subjects for three-dimensional, multi-compartmental in situ visualization of antibiotic concentration-time exposures (area under the curve - AUC), demonstrating preferential brain (AUC tissue/plasma 2...
March 21, 2024: Research Square
https://read.qxmd.com/read/38543282/exploring-variability-in-rifampicin-plasma-exposure-and-development-of-anti-tuberculosis-drug-induced-liver-injury-among-patients-with-pulmonary-tuberculosis-from-the-pharmacogenetic-perspective
#18
JOURNAL ARTICLE
Agnija Kivrane, Viktorija Ulanova, Solveiga Grinberga, Eduards Sevostjanovs, Anda Viksna, Iveta Ozere, Ineta Bogdanova, Maksims Zolovs, Renate Ranka
Genetic polymorphisms can exert a considerable impact on drug pharmacokinetics (PK) and the development of adverse drug reactions (ADR). However, the effect of genetic polymorphisms on the anti-tuberculosis (anti-TB) drug, and particularly rifampicin (RIF), exposure or anti-TB drug-induced liver injury (DILI) remains uncertain. Here, we evaluated the relationship between single nucleotide polymorphisms (SNPs) detected in the RIF pharmacogenes ( AADAC , SLCO1B1 , SLCO1B3 , ABCB1 , and NR1I2 ) and RIF PK parameters, as well as anti-TB treatment-associated DILI...
March 12, 2024: Pharmaceutics
https://read.qxmd.com/read/38543162/new-pyrazolyl-thioureas-active-against-the-staphylococcus-genus
#19
JOURNAL ARTICLE
Anna Maria Schito, Debora Caviglia, Susanna Penco, Andrea Spallarossa, Elena Cichero, Bruno Tasso, Chiara Brullo
To meet the urgent need for new antibacterial molecules, a small library of pyrazolyl thioureas (PTUs) was designed, synthesized and tested against difficult-to-treat human pathogens. The prepared derivatives are characterized by a carboxyethyl functionality on C4 and different hydroxyalkyl chains on N1. Compounds 1a - o were first evaluated against a large panel of Gram-positive and Gram-negative pathogens. In particular, the majority of PTUs proved to be active against different species of the Staphylococcus genus, with MIC values ranging from 32 to 128 µg/mL on methicillin-resistant Staphylococcus strains, often responsible for severe pulmonary disease in cystic fibrosis patients...
March 15, 2024: Pharmaceuticals
https://read.qxmd.com/read/38530588/predictions-of-bedaquiline-central-nervous-system-exposure-in-patients-with-tuberculosis-meningitis-using-physiologically-based-pharmacokinetic-modeling
#20
JOURNAL ARTICLE
Krina Mehta, Pavel Balazki, Piet H van der Graaf, Tingjie Guo, J G Coen van Hasselt
BACKGROUND AND OBJECTIVE: The use of bedaquiline as a treatment option for drug-resistant tuberculosis meningitis (TBM) is of interest to address the increased prevalence of resistance to first-line antibiotics. To this end, we describe a whole-body physiologically based pharmacokinetic (PBPK) model for bedaquiline to predict central nervous system (CNS) exposure. METHODS: A whole-body PBPK model was developed for bedaquiline and its metabolite, M2. The model included compartments for brain and cerebrospinal fluid (CSF)...
March 26, 2024: Clinical Pharmacokinetics
keyword
keyword
67812
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.